Processa Pharmaceuticals

PCSA

Market cap $7.2M

PCSA Hedge Fund Activity: Q1 2026 in Review

10 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q1 2026, worth a combined $448K — up 35% from $331K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PCSA positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Connective Capital Management, opening a new position worth an estimated $193K. The largest seller was Jane Street, exiting entirely with an estimated $86.9K sold.

• 10 institutional investors held Processa Pharmaceuticals (PCSA) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $448K of Processa Pharmaceuticals stock for Q1 2026, up 35% quarter-over-quarter.
• 4 funds opened new Processa Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +1 holder.
• The largest Processa Pharmaceuticals buyer in Q1 2026 was Connective Capital Management, an estimated $193K added.
• The largest Processa Pharmaceuticals seller in Q1 2026 was Jane Street, an estimated $86.9K sold.

Based on aggregated 13F filings for Q1 2026.